Crinetics Pharmaceuticals (CRNX) EPS (Weighted Average and Diluted) (2020 - 2026)
Crinetics Pharmaceuticals (CRNX) recorded quarterly EPS (Weighted Average and Diluted) of -$1.23 in Q1 2026, up 4.65% quarter-over-quarter from -$1.29 in Q4 2025, and down 18.27% on a YoY basis from -$1.5 in Q1 2025.
Crinetics Pharmaceuticals (CRNX) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Crinetics Pharmaceuticals' EPS (Weighted Average and Diluted) history runs 7 years deep, the most recent figure standing at -$1.23 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 18.27% year-over-year to -$1.23; the TTM figure through Mar 2026 stood at -$5.13 (down 34.65% YoY), while the FY2025 annual figure was -$4.95, down 34.15% from the prior year.
- EPS (Weighted Average and Diluted) was -$1.23 for Q1 2026 at Crinetics Pharmaceuticals, up from -$1.29 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.73 in Q1 2022 to a low of -$1.38 in Q3 2025.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.98 across 5 years, with a median of -$0.94 in 2023.
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) climbed 4.95% in 2024, then plunged 48.28% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.83 in 2022, then slipped by 6.02% to -$0.88 in 2023, then grew by 1.14% to -$0.87 in 2024, then slumped by 48.28% to -$1.29 in 2025, then increased by 4.65% to -$1.23 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$1.23 (Q1 2026), -$1.29 (Q4 2025), and -$1.38 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 0.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -0.61 |
| 10 | Crinetics Pharmaceuticals | 3.58 Bn | 3.58 Bn | 10.53 Mn | -1.23 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.23 |
| Dec 31, 2025 | -1.29 |
| Sep 30, 2025 | -1.38 |
| Jun 30, 2025 | -1.23 |
| Mar 31, 2025 | -1.04 |
| Dec 31, 2024 | -0.87 |
| Sep 30, 2024 | -0.96 |
| Jun 30, 2024 | -0.94 |
| Mar 31, 2024 | -0.93 |
| Dec 31, 2023 | -0.88 |
| Sep 30, 2023 | -1.01 |
| Jun 30, 2023 | -0.94 |
| Mar 31, 2023 | -0.85 |
| Dec 31, 2022 | -0.83 |
| Sep 30, 2022 | -0.78 |
| Jun 30, 2022 | -0.81 |
| Mar 31, 2022 | -0.73 |
| Dec 31, 2021 | -0.80 |
| Sep 30, 2021 | -0.73 |
| Jun 30, 2021 | -0.70 |